Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Cheng received an MD from Kunming Medical College Kunming China in 1983 He completed training as a resident surgeon in the Department of Surgery Yunnan Red Cross Hospital Kunming China 19831987 and pathology training at Beijing Medical University receiving a Master in Pathology degree in 1990 He then served as an instructor in the Department of Pathology at Beijing Medical University from September 1990 until August 1993 when he joined the research program of Professor Rudy Juliano the Chairman of the Department of Pharmacology at the University of North Carolina Chapel Hill where he was awarded a PhD in Pharmacology in 1997 He initiated postdoctoral training with Dr Juliano 19971998 and then joined the research program of Transcriptional Regulation in the Laboratory of Dr Mark Ptashne an Albert Lasker Basic Award winner at Memorial Sloan Kettering Cancer Center In 2004 Dr Cheng began residency training in Anatomic and Clinical Pathology at the University of Chicago Following residency training he initiated and completed subspecialty training with Dr James Vardiman in Hematopathology at the University of Chicago 20082010 Meanwhile he also worked with Dr Harinder Singh on PU1 and Transcriptional Regulations of Hematopoiesis at University of Chicago Dr Cheng was selected as the recipient of the PathologistinTraining Award from the Society of Hematopathology and received the Paul E Strandjord Young Investigator Award from Academy of Clinical Physicians and Scientists in 2008 Dr Cheng is a member of the United States and Canadian Academy of Pathology the American Society of Hematology American Cancer Society for Research and the American Society for Clinical Pathology He is board certified in anatomic and clinical pathology hematopathology Dr Cheng joined the faculty of the Department of Pathology as Assistant Professor in April 2010
Dr. Jason Cheng’s research is aimed at understanding epigenetic and genetic controls of both normal and abnormal hematopoiesis, especially, myelopoiesis. Dr. Jason Cheng’s laboratory is currently developing and implementing new technologies for genome-wide profiling of epigenetic biomarkers/signatures and exploring their potential clinical use for assisting diagnosis, prognosis and therapeutic management of myelodysplastic syndrome (MDS), leukemia and other diseases. Another major effort in Dr. Cheng’s laboratory is to elucidate pathogenetic mechanisms underlying epigenetic alterations in MDS, leukemia and bone marrow diseases. Dr. Jason Cheng’s clinical interests include general hematopathology, myelodysplastic syndrome (MDS), myeloproliferative neoplasms, other bone marrow diseases and lymphoid disorders.
|Editorial: J Clinic Experiment Pathol 2011, 1: e103|
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals